Search


Current filters:

Clear current filters  or Add more filters

View Option



Results 1-10 of 64 (Search time: 0.067 seconds).

  Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration (Journal article)

  Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study (Journal article)

  Contralateral prophylactic mastectomy: mind the genetics (Journal article)

  Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group (Journal article)

  Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression (Journal article)

  Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group (Journal article)

  G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting (Journal article)

  Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study (Journal article)

  First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study (Journal article)